RecoBiaTx is a biopharmaceutical company focused on expanding patient access to advanced cancer biotherapies by transitioning treatments from intravenous to subcutaneous administration. This approach offers a faster, more convenient delivery method that is preferred by both patients and hospitals. The company aims to make cutting-edge cancer treatments more broadly accessible through this innovative delivery model.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced cancer biotherapies are predominantly administered intravenously, requiring lengthy infusion sessions that are inconvenient for patients and resource-intensive for hospitals. This delivery method limits patient access to cutting-edge treatments, particularly for those who face logistical challenges attending frequent clinic visits.
Solution
RecoBiaTx is developing a transition from intravenous to subcutaneous administration for cancer biotherapies, making these advanced treatments faster and more convenient to deliver. Subcutaneous injection significantly reduces administration time compared to IV infusion, easing the burden on hospital resources and improving the patient experience. This approach broadens access to cutting-edge cancer treatments by enabling administration in a wider range of healthcare settings. The company's vision is to facilitate access to advanced cancer treatments for everyone, everywhere through this more practical delivery method.
Target Audience
Primary customers are hospitals, oncology clinics, and healthcare providers seeking more efficient and patient-friendly methods for administering advanced cancer biotherapies.
Features
- Subcutaneous formulation of cancer biotherapies designed to replace standard intravenous delivery
- Reduced administration time compared to traditional IV infusion protocols
- Delivery method compatible with a broader range of healthcare settings beyond infusion centers
- Patient-centered approach that improves convenience and comfort during treatment